Mar 14, 2023 / 07:05PM GMT
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst
Good afternoon, everyone and welcome to Barclays Global Healthcare Conference. We're in Miami, and do raise your hand or e-mail us if you have questions. My name is Peter Lawson. I'm one of the mid-cap biotech analyst at Barclays, focusing on oncology, really delighted to have up on stage with me, the CEO from Fate, Scott Wolchko.
Questions and Answers:
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research AnalystAnd I guess the first question is really kind of I guess, opponent from most people is just kind of J&J collaboration kind of how that unfolded if you can kind of shed any more light around...
J. Scott Wolchko - Fate Therapeutics, Inc. - Founder, CEO, President & Director
Sure -- I mean I'll do as best as I can with it. It certainly is a bit of a surprise. We were making a lot of progress under the J&J collaboration. Headed into the fourth quarter, J&J had already exercised a commercial